Last edition
News about "KER-0193"
Servier to Acquire KER-0193 from Kaerus Bioscience in Deal Worth Up to USD 450 Million
Servier has signed a definitive agreement to acquire KER-0193 from Kaerus Bioscience, a potential first-in-disease treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder.
KER-0193 | 08/09/2025 | By Mrinmoy Dey | 100
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members